{"log_id": 4020100731036401758, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0.000135, "average": 0.991565, "min": 0.961931}, "location": {"width": 170, "top": 166, "height": 28, "left": 156}, "words": "吸收和生物利用度"}, {"probability": {"variance": 0.00445, "average": 0.983618, "min": 0.566327}, "location": {"width": 885, "top": 202, "height": 41, "left": 197}, "words": "阿戈美拉汀口服后吸收快速且良好(≥80%)。绝对生物利用度低(口服治疗剂量<5%),个体间"}, {"probability": {"variance": 1.4e-05, "average": 0.998127, "min": 0.979569}, "location": {"width": 928, "top": 249, "height": 44, "left": 155}, "words": "差异较大。与男性个体相比,女性的生物利用度较高。口服避孕药会增加药物的生物利用度,而吸烟会"}, {"probability": {"variance": 3e-06, "average": 0.999219, "min": 0.990968}, "location": {"width": 502, "top": 305, "height": 35, "left": 155}, "words": "使生物利用度降低。服药后1~2小时内达到血浆峰浓度"}, {"probability": {"variance": 1.4e-05, "average": 0.998568, "min": 0.977133}, "location": {"width": 886, "top": 345, "height": 44, "left": 198}, "words": "在治疗剂量范围内,阿戈美拉汀的系统暴露随剂量升高而成比例地增加。高剂量时,首过效应达"}, {"probability": {"variance": 0, "average": 0.999794, "min": 0.99974}, "location": {"width": 67, "top": 409, "height": 24, "left": 154}, "words": "到饱和"}, {"probability": {"variance": 1.4e-05, "average": 0.997679, "min": 0.981401}, "location": {"width": 888, "top": 441, "height": 42, "left": 197}, "words": "进食(标准饮食或高脂饮食)不影响阿戈美拉汀的生物利用度或吸收率。高脂饮食会增加个体差"}, {"probability": {"variance": 0, "average": 0.999921, "min": 0.999921}, "location": {"width": 25, "top": 504, "height": 24, "left": 155}, "words": "异"}, {"probability": {"variance": 3e-06, "average": 0.99805, "min": 0.996277}, "location": {"width": 47, "top": 551, "height": 24, "left": 157}, "words": "分布"}, {"probability": {"variance": 0.000214, "average": 0.995116, "min": 0.920088}, "location": {"width": 888, "top": 582, "height": 43, "left": 197}, "words": "稳态分布容积约为35L,血浆蛋白结合率为95%,与药物血浆浓度无关,不受个体年龄或者肾脏功"}, {"probability": {"variance": 3e-06, "average": 0.998725, "min": 0.993271}, "location": {"width": 502, "top": 637, "height": 35, "left": 155}, "words": "能的影响。但肝功能损害患者游离药物浓度可升高一倍"}, {"probability": {"variance": 4e-06, "average": 0.998674, "min": 0.99541}, "location": {"width": 85, "top": 694, "height": 25, "left": 157}, "words": "生物转化"}, {"probability": {"variance": 0.00116, "average": 0.990324, "min": 0.774338}, "location": {"width": 890, "top": 727, "height": 40, "left": 195}, "words": "阿戈美拉汀口服后主要经肝脏 CYPIA2同工酶迅速代谢,CYP2C9和CYP2C19同工酶也参与阿戈"}, {"probability": {"variance": 2e-06, "average": 0.99872, "min": 0.995909}, "location": {"width": 250, "top": 785, "height": 29, "left": 155}, "words": "美拉汀的代谢,但作用较小"}, {"probability": {"variance": 5e-06, "average": 0.999127, "min": 0.986082}, "location": {"width": 857, "top": 822, "height": 39, "left": 199}, "words": "主要代谢产物羟化阿戈美拉汀和去甲基阿戈美拉汀均无活性且在体内迅速结合,并经尿液排出"}, {"probability": {"variance": 0, "average": 0.999531, "min": 0.999519}, "location": {"width": 45, "top": 883, "height": 25, "left": 157}, "words": "消除"}, {"probability": {"variance": 0.000221, "average": 0.99421, "min": 0.921372}, "location": {"width": 864, "top": 916, "height": 41, "left": 196}, "words": "阿戈美拉汀消除速率快,平均的血浆消除半衰期为1~2小时,清除率较高(约为1100mL/min)"}, {"probability": {"variance": 1e-06, "average": 0.999199, "min": 0.994646}, "location": {"width": 687, "top": 969, "height": 36, "left": 156}, "words": "主要以代谢产物的形式经尿液排泄(80%),其中原型药物成分可忽略不计"}, {"probability": {"variance": 3e-06, "average": 0.999165, "min": 0.992246}, "location": {"width": 381, "top": 1020, "height": 32, "left": 199}, "words": "重复给药不会改变药物的药代动力学过程"}, {"probability": {"variance": 3e-06, "average": 0.998369, "min": 0.995369}, "location": {"width": 86, "top": 1074, "height": 25, "left": 158}, "words": "肾脏损害"}, {"probability": {"variance": 7e-06, "average": 0.998233, "min": 0.985507}, "location": {"width": 885, "top": 1109, "height": 39, "left": 199}, "words": "在严重肾脏损伤患者中,药代动力学参数未发生相关改变(n=8,25mg单剂量)。但是,由于中"}, {"probability": {"variance": 9e-06, "average": 0.998399, "min": 0.984494}, "location": {"width": 924, "top": 1156, "height": 40, "left": 155}, "words": "度或重度肾功能损害患者使用阿戈美拉汀的临床资料有限,因此给该类患者处方时需谨慎。(参见【用"}, {"probability": {"variance": 5e-06, "average": 0.996977, "min": 0.99395}, "location": {"width": 97, "top": 1216, "height": 26, "left": 155}, "words": "法用量】)"}, {"probability": {"variance": 0.00248, "average": 0.865669, "min": 0.815866}, "location": {"width": 86, "top": 1222, "height": 31, "left": 940}, "words": " GROUP CO"}, {"probability": {"variance": 0, "average": 0.999676, "min": 0.999399}, "location": {"width": 108, "top": 1265, "height": 25, "left": 157}, "words": "肝功能损害"}, {"probability": {"variance": 0.009984, "average": 0.970807, "min": 0.458175}, "location": {"width": 889, "top": 1296, "height": 44, "left": 198}, "words": "在一项专门针对伴有慢性轻度( Child- Pugh type A)或中度( Child- Pugh type B)肝损害的肝硬化"}, {"probability": {"variance": 6.4e-05, "average": 0.997452, "min": 0.946759}, "location": {"width": 930, "top": 1345, "height": 41, "left": 156}, "words": "患者的研究中,与相匹配(年龄、体重、吸烟习惯)的无肝损害的志愿者相比,轻、中度肝损害患者服"}, {"probability": {"variance": 0.000124, "average": 0.996218, "min": 0.929192}, "location": {"width": 931, "top": 1391, "height": 44, "left": 155}, "words": "用25mg阿戈美拉汀的暴露量显著升高(分别升高70倍和140倍)(参见【用法用量】、【禁忌】和"}, {"probability": {"variance": 0.00011, "average": 0.995352, "min": 0.969714}, "location": {"width": 130, "top": 1453, "height": 25, "left": 164}, "words": "【注意事项】)"}, {"probability": {"variance": 0, "average": 0.99942, "min": 0.998404}, "location": {"width": 86, "top": 1502, "height": 25, "left": 159}, "words": "老年人群"}, {"probability": {"variance": 7.3e-05, "average": 0.996151, "min": 0.95542}, "location": {"width": 889, "top": 1536, "height": 42, "left": 197}, "words": "在一项老年患者(≥65岁)中进行药代动力学研究中,已证实在25mg剂量下,同<75岁患者相"}], "language": 3}